Abbott Laboratories (ABT) news

Abbott - To launch Libre Duo 10 day in U.S. later this year

Abbott has announced plans to launch its Libre Duo 10 Day dual glucose-ketone monitoring system in the United States later this year, pending regulatory approval . The system, which received CE Mark in May 2026, is designed to provide real-time monitoring of both glucose and ketone levels, offering…

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes

FDA clears Abbott's Libre Duo for patients aged 2 and older

Abbott has received CE Mark approval for its Libre Duo and Libre Duo 10 Day systems, marking dual glucose-ketone sensing technology . These biowearables continuously monitor both glucose and ketone levels, offering real-time data to help detect rising ketone levels that could lead to diabetic…

FDA clears Abbott Libre Duo 10 day dual glucose ketone monitor

Abbott has announced that it has secured CE Mark for its Libre Duo and Libre Duo 10 Day systems, the first continuous glucose and ketone monitoring devices to receive regulatory approval in Europe. These systems are designed to provide real-time data on both glucose and ketone levels, offering a…

Abbott International: reached $1.2 bln in assets under management as of June 30, 2026

Abbott International reported a significant milestone in its financial performance, reaching $1.2 billion in assets under management as of June 30, 2026. This figure reflects a strong quarter for the company, demonstrating continued growth and stability in its portfolio. The increase in assets…